A detailed history of Triangle Securities Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Triangle Securities Wealth Management holds 1,830 shares of VRTX stock, worth $862,149. This represents 0.25% of its overall portfolio holdings.

Number of Shares
1,830
Previous 1,850 1.08%
Holding current value
$862,149
Previous $773,000 10.87%
% of portfolio
0.25%
Previous 0.22%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

SELL
$392.81 - $485.53 $7,856 - $9,710
-20 Reduced 1.08%
1,830 $857,000
Q1 2024

Apr 10, 2024

SELL
$407.69 - $446.08 $17,530 - $19,181
-43 Reduced 2.27%
1,850 $773,000
Q4 2023

Jan 10, 2024

SELL
$343.0 - $410.68 $33,614 - $40,246
-98 Reduced 4.92%
1,893 $770,000
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $53,770 - $57,631
-159 Reduced 7.4%
1,991 $692,000
Q2 2023

Jul 13, 2023

SELL
$314.42 - $351.91 $62,884 - $70,382
-200 Reduced 8.51%
2,150 $756,000
Q1 2023

Apr 20, 2023

SELL
$283.23 - $323.1 $16,427 - $18,739
-58 Reduced 2.41%
2,350 $740,000
Q4 2022

Jan 11, 2023

SELL
$285.76 - $321.48 $128,592 - $144,666
-450 Reduced 15.75%
2,408 $0
Q3 2022

Oct 19, 2022

SELL
$273.83 - $305.53 $56,135 - $62,633
-205 Reduced 6.69%
2,858 $828,000
Q2 2022

Jul 11, 2022

BUY
$234.96 - $292.55 $40,648 - $50,611
173 Added 5.99%
3,063 $863,000
Q1 2022

Apr 13, 2022

SELL
$221.42 - $260.97 $57,126 - $67,330
-258 Reduced 8.2%
2,890 $754,000
Q4 2021

Jan 14, 2022

BUY
$177.01 - $223.45 $23,896 - $30,165
135 Added 4.48%
3,148 $691,000
Q3 2021

Oct 14, 2021

BUY
$181.39 - $202.99 $77,090 - $86,270
425 Added 16.42%
3,013 $547,000
Q2 2021

Jul 12, 2021

BUY
$187.49 - $221.1 $485,224 - $572,206
2,588 New
2,588 $522,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Triangle Securities Wealth Management Portfolio

Follow Triangle Securities Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Triangle Securities Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Triangle Securities Wealth Management with notifications on news.